Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Share-based Compensation (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Share-based Compensation for 4 consecutive years, with $118383.0 as the latest value for Q4 2024.

  • Quarterly Share-based Compensation rose 69.26% to $118383.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $195103.0 through Dec 2024, down 64.13% year-over-year, with the annual reading at $297467.0 for FY2025, 61.55% down from the prior year.
  • Share-based Compensation hit $118383.0 in Q4 2024 for Pasithea Therapeutics, up from $2360.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $720000.0 in Q4 2021 to a low of -$270000.0 in Q3 2021.
  • Historically, Share-based Compensation has averaged $132791.2 across 4 years, with a median of $111000.0 in 2022.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 141.11% in 2022 and later plummeted 98.79% in 2024.
  • Year by year, Share-based Compensation stood at $720000.0 in 2021, then crashed by 78.31% to $156174.0 in 2022, then crashed by 55.22% to $69940.0 in 2023, then skyrocketed by 69.26% to $118383.0 in 2024.
  • Business Quant data shows Share-based Compensation for KTTA at $118383.0 in Q4 2024, $2360.0 in Q3 2024, and $2360.0 in Q2 2024.